Holen Sie sich die Stockscreener-App
12.99
1.52%
-0.20
Handel nachbörslich:
12.99
Schlusskurs vom Vortag:
$13.19
Offen:
$13.25
24-Stunden-Volumen:
1.58M
Relative Volume:
0.54
Marktkapitalisierung:
$1.96B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-647.68M
KGV:
-2.291
EPS:
-5.67
Netto-Cashflow:
$-594.49M
1W Leistung:
-4.63%
1M Leistung:
-9.67%
6M Leistung:
+50.87%
1J Leistung:
-6.01%
1-Tages-Spanne:
$12.77
$13.35
1-Wochen-Bereich:
$12.76
$14.97
52-Wochen-Spanne:
$7.48
$18.57
Biohaven Ltd Stock (BHVN) Company Profile
Firmenname
Biohaven Ltd
Sektor
Branche
Telefon
203-404-0410
Adresse
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
12.99 | 1.96B | 0 | -647.68M | -594.49M | -5.67 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-02-06 | Eingeleitet | Goldman | Buy |
| 2026-01-21 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-12-03 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-11-26 | Herabstufung | UBS | Buy → Neutral |
| 2025-11-06 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2025-11-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-09-17 | Eingeleitet | Citigroup | Buy |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-05-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-09-16 | Eingeleitet | Jefferies | Buy |
| 2024-09-04 | Eingeleitet | Bernstein | Outperform |
| 2024-07-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2023-12-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-01-24 | Eingeleitet | SVB Securities | Outperform |
| 2023-01-04 | Eingeleitet | JP Morgan | Overweight |
| 2022-12-02 | Eingeleitet | BTIG Research | Buy |
| 2022-10-26 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-05-11 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-08-10 | Herabstufung | UBS | Buy → Neutral |
| 2021-08-03 | Bestätigt | Canaccord Genuity | Buy |
| 2021-03-11 | Eingeleitet | UBS | Buy |
| 2020-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-17 | Eingeleitet | Cowen | Outperform |
| 2020-02-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2019-11-22 | Eingeleitet | Wedbush | Outperform |
| 2019-06-25 | Bestätigt | Canaccord Genuity | Buy |
| 2019-05-06 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | Bestätigt | Needham | Buy |
| 2018-07-03 | Bestätigt | Needham | Buy |
| 2018-07-02 | Bestätigt | Needham | Buy |
| 2018-04-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2018-02-22 | Bestätigt | Canaccord Genuity | Buy |
| 2017-12-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-10-03 | Bestätigt | Needham | Buy |
Alle ansehen
Biohaven Ltd Aktie (BHVN) Neueste Nachrichten
Biohaven Ltd. (BHVN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Biohaven Ltd. (BHVN) stock price, news, quote and history - sg.finance.yahoo.com
Has Biohaven (BHVN) Fallen Far Enough to Look Fully Priced? - Yahoo Finance
BHVN News | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout - Stocktwits
Yale, Biohaven Seek $23M Atty Fee After Trade Secrets Win - law360.com
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 49.55% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Biohaven (BHVN) Gains Attention As Pipeline Hopes Meet A Big Fair Value Gap - simplywall.st
Biohaven's Kv7 Program Remains Key Stock Driver, UBS Says - finance.yahoo.com
Biohaven (BHVN) discloses options tied to SVP's son - Stock Titan
Biohaven (BHVN) 10K Form and Latest SEC Filings 2026 - MarketBeat
Biohaven Advanced BHV-7000 to Pivotal Trials Without Answering a Question the FDA Requires Every Sponsor to Answer - The Clinical Trial Vanguard
Biohaven (BHVN) Could Be 82% Undervalued Following FDA Hold On Opakalim Trials - simplywall.st
Biohaven Faces New Securities Investigation - stl.news
Biohaven Ltd. (BHVN) Securities Fraud InvestigationLevi & Korsinsky - ACCESS Newswire
Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN) - PR Newswire
Why Is Biohaven (NYSE:BHVN) Opakalim Under FDA Hold on NYSE Composite? - Kalkine Media
What Does Biohaven (BHVN) FDA Hold Mean For Its Opakalim Program? - simplywall.st
Biohaven’s epilepsy drug hit with FDA clinical hold - Yahoo Finance
Biohaven pauses new enrollment in epilepsy trials after FDA partial clinical hold By Investing.com - Investing.com South Africa
BHVN Stock Builds Momentum Ahead Of Multiple H2 2026 Clinical Data Readouts - Stocktwits
Biohaven’s Newly Out-Licensed Epilepsy Drug Put On A Partial Clinical Hold - insights.citeline.com
Biohaven: The Hold Isn't The Problem (Rating Downgrade) (NYSE:BHVN) - Seeking Alpha
Why is Biohaven Pharmaceutical stock sliding today? - investing.com
Biohaven Shares Plunge as FDA Halts New Enrollment in Epilepsy Drug Trials - finance.biggo.com
BHVN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10 - GuruFocus
FDA pauses enrollment in Biohaven’s opakalim trials; pivotal readout remains on track - AllSci
Baird reiterates Biohaven stock rating after regulatory update By Investing.com - Investing.com Nigeria
BHVN Stock Slips As Kv7 Deal Seen As Stopgap Move - StocksToTrade
BHVN Stock Slips As SK Deal Seen As Buying Time - timothysykes.com
Baird reiterates Biohaven stock rating after regulatory update - Investing.com
US FDA pauses new enrollment in Biohaven's epilepsy drug trials - Reuters
Why Is Biohaven Stock Tumbling Today?Biohaven (NYSE:BHVN) - Benzinga
FDA Places Partial Clinical Hold on Biohaven’s BHV-7000 Epilepsy Enrollment - Minichart
Biohaven Shares Fall 17% After FDA Places Partial Hold on BHV-7000 Trials - Yahoo Finance
BHVN Stock Crashes 10% – Why Did FDA Put Biohaven’s Epilepsy Trial On Partial Hold? - Yahoo Finance
FDA places partial hold on Biohaven’s epilepsy drug - Yahoo Finance
Form 8K Biohaven Pharmaceutical Holding Co For: 10 September By Investing.com - Investing.com Nigeria
Biohaven stock tumbles after pausing trial enrollment By Investing.com - Investing.com South Africa
Biohaven stock tumbles after pausing trial enrollment - Investing.com
Biohaven faces partial FDA hold on BHV-7000 program - TipRanks
Biohaven pauses new enrollment in epilepsy trials after FDA partial clinical hold - Investing.com Canada
Form 8K Biohaven Pharmaceutical Holding Co For: 10 September - Investing.com India
FDA puts partial hold on Biohaven (NYSE: BHVN) epilepsy trial as 600+ patients keep dosing - Stock Titan
Is Biohaven (BHVN) Priced At A Premium After Its 36% Rise? - simplywall.st
Technical Reactions to BHVN Trends in Macro Strategies - Stock Traders Daily
Biohaven Pharma stock falls after RBC Capital downgrade By Investing.com - Investing.com India
Biohaven Stock Seen Range-Bound as Near-Term Catalysts Fade, RBC Says - marketscreener.com
Biohaven stock downgraded at RBC Capital Markets (BHVN:NYSE) - Seeking Alpha
Biohaven Pharma stock falls after RBC Capital downgrade - investing.com
Finanzdaten der Biohaven Ltd-Aktie (BHVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):